The Open Dentistry Journal

Current Trends in Anticancer Drug Delivery System other than or in Combination with Conventional Therapy in Oral cancer - A Comprehensive Review

Neeraj Taneja1,*, Aftab Alam2, Ranjana S Patnaik1 and Tannu Taneja3

1School of Biological & Biomedical Sciences, Galgotias University, Greater Noida, India
2Department of Pharmacy, Galgotias University, Greater Noida, India
3Department of Oral Pathology and Microbiology Sri Sukhmani Dental College & Hospital, Dera Bassi, Mohali, India

Table 1. PRISMA 2020 Checklist.

<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item #</th>
<th>Checklist item</th>
<th>Location where item is reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review.</td>
<td>Page 1 Line 2</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract</td>
<td>2</td>
<td>See the PRISMA 2020 for Abstracts checklist.</td>
<td>Page 1 Line 20</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of existing knowledge.</td>
<td>Page 3 Line 58</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of the objective(s) or question(s) the review addresses.</td>
<td>Page 3 Line 60</td>
</tr>
<tr>
<td>METHODS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>5</td>
<td>Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.</td>
<td>Page 4 Line 90, Page 4 Line 94,95</td>
</tr>
<tr>
<td>Information sources</td>
<td>6</td>
<td>Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.</td>
<td>Page 4 Line 84,85, 88</td>
</tr>
<tr>
<td>Search strategy</td>
<td>7</td>
<td>Present the full search strategies for all databases, registers and websites, including any filters and limits used.</td>
<td>Page 4 Line 84</td>
</tr>
<tr>
<td>Selection process</td>
<td>8</td>
<td>Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.</td>
<td>Page 4 Line 83-95</td>
</tr>
<tr>
<td>Data collection process</td>
<td>9</td>
<td>Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.</td>
<td>Page 4 Line 93</td>
</tr>
<tr>
<td>Data items</td>
<td>10a</td>
<td>List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.</td>
<td>Page 5 Line 96-103</td>
</tr>
<tr>
<td></td>
<td>10b</td>
<td>List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>
Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. Page 4 Line 93

Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. Not Applicable

Synthesis methods 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). Page 4,5 Line 84-98

13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. Not Applicable

13c Describe any methods used to tabulate or visually display results of individual studies and/or syntheses. Page 27-30 Table 1,2,3

13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. Not Applicable

13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). Not Applicable

13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. Page 30 Table 3

Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). Page 4 Line 93

Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. Page 30 Table 3

RESULTS

Study selection 16a Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. Page 23 Figure 1

16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. Page 23 Figure 1

Study characteristics 17 Cite each included study and present its characteristics. Page 23 Figure 1

Risk of bias in studies 18 Present assessments of risk of bias for each included study. Page 4 Line 93

Results of individual studies 19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. Page 27-30 Table 1,2,3

Results of syntheses 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. Page 24-30 Figure 2,3,4 Table 1,2,3

20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval), and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. Page 24-30 Figure 2,3,4 Table 1,2,3

20c Present results of all investigations of possible causes of heterogeneity among study results. Page 24-30 Figure 2,3,4 Table 1,2,3

20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. Page 24-30 Figure 2,3,4 Table 1,2,3

Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. Table 4 Line 93

Certainty of evidence 22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. Page 6 Line 24 onwards

DISCUSSION

Discussion 23a Provide a general interpretation of the results in the context of other evidence. Page 6 Line 24 onwards

23b Discuss any limitations of the evidence included in the review. Page 19 Line 440

23c Discuss any limitations of the review processes used. Page 19 Line 440

23d Discuss implications of the results for practice, policy, and future research. Page 26 Line 440

OTHER INFORMATION

Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state that the review was not registered. Not Applicable

24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. Not Applicable

24c Describe and explain any amendments to information provided at registration or in the protocol. Not Applicable

Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. Page 22 Line 494

Competing interests 26 Declare any competing interests of review authors. Page 22 Line 497
Availability of data, code and other materials

Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.

Page 30 Table 3


© 2022 Taneja et al.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.